To observe the clinical efficacy and safety of polymyxin B injection combined with sitafloxacin tablets in the treatment of hospital-acquired pneumonia (HAP) caused by extensively drug-resistant Pseudomonas aeruginosa.

Patients with pandrug-resistant pseudomonas aeruginosa (PDR-PA) pneumonia admitted to our hospital were enrolled. According to treatment regimen, patients were divided into control group and treatment group. Patients in the control group received polymyxin B injection at an initial dose of 2.0-2.5 mg·kg^-1, followed by a maintenance dose of 1.25-1.5 mg·kg^-1 every 12 h after the loading dose. Patients in the treatment group received additional oral sitafloxacin tablets at 50-100 mg twice daily on the basis of the above regimen. The duration of antibacterial treatment for both groups was 7 days in principle, with a maximum of 14 days. Clinical efficacy, bacterial clearance rate, inflammatory markers, arterial blood gas and oxygenation parameters, prognosis, and safety profiles were compared between two groups.

A total of 128 patients were included in this study, with 64 cases in each group. After treatment, the total effective rates in the control group and the treatment group were 76.56% (49 cases/64 cases) and 95.31% (61 cases/64 cases), showing a statistically significant difference (P<0.05). After treatment, the total bacterial clearance rates in control and treatment groups were were 73.44% (47 cases/64 cases) and 93.75% (60 cases/64 cases), respectively; the serum levels of procalcitonin (PCT) were (1.42±0.31) and (0.81±0.18) ng·mL^-1, respectively; C-reactive protein (CRP) were (68.14±15.62) and (38.27±12.46) mg·L^-1, respectively; and interleukin-6 (IL-6) were (61.73±14.85) and (38.92±11.77) pg·mL^-1, respectively; the arterial partial pressure of oxygen (PaO₂) were (75.36±7.15) and (88.57±6.93) mmHg, respectively; the arterial partial pressure of carbon dioxide (PaCO₂) were (45.27±4.86) and (39.68±4.25) mmHg, respectively; and the oxygenation index (PaO₂/FiO₂) were 236.48±28.51 and 278.36±31.22, respectively. All of these indicators in treatment group showed statistically significant differences compared to control group (all P<0.05). The 28-day all-cause mortality rates of the control group and the treatment group were 10.94% (7 cases/64 cases) and 4.69% (3 cases/64 cases), respectively; and the length of hospital stay were (15.82±4.27) and (14.97±3.58) d, respectively; with no significant differences between the two groups (all P>0.05). The incidences of total adverse drug reactions in the treatment group and the control group were 18.75% (12 cases/64 cases) and 25.00% (16 cases /64 cases), respectively, with no statistically significant difference between the two groups (P>0.05).

Polymyxin B injection combined with sitafloxacin tablets significantly improves bacterial clearance, reduces inflammatory response, and enhances oxygenation in patients with xDR-PA HAP, while maintaining good safety, indicating its potential clinical utility.

To explore the intervention effect of jiedu dihuang decoction on the inflammatory microenvironment of colon cancer by regulating mitophagy and nucleotide - binding oligomerization domain (NOD) like receptor hot protein domain-related protein 3 (NLRP3) inflammasome.

The animal model was successfully replicated by intraperitoneal injection of azoxymethane (AOM) combined with feeding dextran sodium sulfate (DSS). The animals were randomly divided into A: control group, B: model group, C, D, E: Jiedu Dihuang Decoction low, medium and high dose group, F: positive drug group. Ninety male C57BL/6 mice were randomly divided into 6 groups of 15 mice each, and all groups were treated continuously for 10 weeks. The pathological changes of rectal tissue were evaluated by hematoxylin-eosin (HE) staining. Immunofluorescence staining was used to observe the expression site and intensity of PTEN-induced kinase 1 (PINK1), Parkinson’s disease protein (Parkin) and B-cell lymphoma-2-interacting myosin-like coiled-coil protein 1 (Beclin1) in colon tissue. The expression of NLRP3, apoptosis-associated speck-like protein (ASC) and Caspase-1 mRNA in rectum was detected by polymerase chain reaction (PCR). The protein expression levels of PINK1, Parkin, Beclin1, NLRP3, ASC and Caspase-1 were detected by Western blotting (WB). The ratio of helper T cell 1 (Th1) to helper T cell 2 (Th2) was detected by flow cytometry. The levels of interleukin-4 (IL-4), interleukin-6 (IL-6), interleukin-10 (IL-10), interleukin-12 (IL-12), tumor necrosis factor-α (TNF-α) and interferon-γ (IFN-γ) were detected by enzyme-linked immunosorbent assay (Elisa).

The mRNA expression levels of NLRP3, ASC and Caspase-1 in the model group were 2.06±0.22, 3.03±0.16 and 3.28±0.22, respectively, while those in the control group were 1.01±0.17, 1.01±0.19 and 1.00±0.11, respectively, with statistically significant differences between the two groups (all P<0.01). The mean fluorescence intensities of PINK1, Parkin and Beclin1 in the model group were 76.39±4.89, 83.12±5.01 and 87.43±3.77, respectively, compared with 122.99±6.93, 138.38±3.84 and 143.22±9.42 in the control group, and the differences were statistically significant (all P<0.01). As for the proportion of T helper cells in peritoneal fluid, the model group showed a significantly lower Th1 proportion (0.74±0.09)% and a significantly higher Th2 proportion (2.05±0.26)% compared with the control group [(4.78±0.62)% and (0.26±0.07)%, respectively, all P<0.01]. In terms of peripheral blood cytokine levels, the concentrations of IL-4, IL-6, IL-10 and TNF-α in the model group were (48.98±3.78) pg·mL^-1, (44.42±2.55) pg·mL^-1, (37.67±5.34) pg·mL^-1 and (79.11±6.32) pg·mL^-1, respectively, which were significantly higher than those in the control group [(26.44±5.64) pg·mL^-1, (24.21±2.25) pg·mL^-1, (19.06±3.76) pg·mL^-1 and (35.78±13.17) pg·mL^-1, respectively]. Conversely, the levels of IL-12 and IFN-γ in the model group were (28.28±2.33) ng·mL^-1 and (238.67±35.78) pg·mL^-1, respectively, which were significantly lower than those in the control group [(55.39±3.47) ng·mL^-1 and (517.72±52.15) pg·mL^-1, respectively], with all differences reaching statistical significance (all P<0.01). The mRNA expression levels of NLRP3 in the low, medium, high-dose Jiedu-Dihuang Decoction groups and the positive drug group were 1.75±0.10, 1.59±0.11, 1.31±0.11 and 1.48±0.10, respectively; the mRNA expression levels of ASC were 2.69±0.10, 1.96±0.14, 1.54±0.18 and 1.89±0.09, respectively; and the mRNA expression levels of Caspase-1 were 2.85±0.08, 2.24±0.26, 1.58±0.22 and 1.94±0.16, respectively. Except for the low-dose Jiedu-Dihuang Decoction group, the differences between the other treatment groups and the model group were statistically significant (P<0.05, P<0.01). The mean fluorescence intensities of PINK1 in each treatment group were 87.50±9.38, 98.75±7.13, 107.28±6.60 and 94.75±7.11, respectively; those of Parkin were 94.11±8.17, 103.13±8.59, 111.27±9.66 and 101.27±9.21, respectively; and those of Beclin1 were 100.2±7.11, 107.92±6.84, 122.65±8.36 and 105.44±7.55, respectively. Except for the low-dose Jiedu-Dihuang Decoction group, the differences between the other treatment groups and the model group were statistically significant(P<0.05, P<0.01). The proportions of Th1 in peritoneal fluid of each treatment group were (1.34±0.13)%, (1.78±0.21)%, (2.89±0.23)% and (2.47±0.24)%, respectively; and the proportions of Th2 were (1.65±0.18)%, (1.06±0.11)%, (0.57±0.14)% and (0.68±0.07)%, respectively. Except for the low-dose Jiedu-Dihuang Decoction group, the differences between the other treatment groups and the model group were statistically significant (all P<0.05, P<0.01). The levels of IL-4 in peripheral blood of each treatment group were (41.67±4.31), (36.39±5.93), (33.61±4.30) and (33.94±5.81) pg·mL^-1, respectively; those of IL-6 were (39.10±2.89), (32.85±3.98), (28.91±1.91) and (27.63±1.98) pg·mL^-1, respectively; those of IL-10 were (32.11±7.50), (26.28±4.65), (23.22±4.35) and (26.22±6.15) pg·mL^-1, respectively; those of TNF-α were (64.13±13.12), (57.44±13.62), (47.45±10.06) and (50.78±10.9) pg·mL^-1, respectively; those of IL-12 were (34.09±2.49), (38.53±3.84), (42.67±3.87) and (41.93±4.39) ng·mL^-1, respectively; and those of IFN-γ were (286.57±54.77), (358.59±52.15), (435.28±73.12) and (405.33±39.33) pg·mL^-1, respectively. Except for the low-dose Jiedu-Dihuang Decoction group, the differences between the other treatment groups and the model group were statistically significant(all P<0.05, P<0.01)

Jiedu-Dihuang Decoction can improve the inflammatory microenvironment of colon cancer, which may be related to the regulation of NLRP3 inflammasome by mitochondrial autophagy.

To develop a transdermal delivery system for tetraphydrocurcumin nanoemulsion-gel (Thc@NE@gel), and to investigate its therapeutic efficacy and mechanism of action in atopic dermatitis (AD).

Thc@NE@gel was prepared using a high-energy emulsification method combined with a low-temperature swelling process. The formulation was characterized for particle size, zeta potential, drug loading, encapsulation efficiency, morphology and physicochemical properties. In vitro transdermal absorption experiments were conducted using a Franz diffusion cell. An AD mouse model was established, and successfully induced mice were randomly divided into animal control group, positive drug group (10mg·kg^-1 dexamethasone gel), animal model group, Thc@NE group (Thc@NE 20 mg·kg^-1) and animal Thc@NE@gel low-, medium- and high-dose experimental groups (10, 20, and 30 mg·kg^-1 Thc@NE@gel), with 6 mice in each group. Body weights of mice in each group were measured and changes recorded; hematoxylin and eosin (HE) staining was performed to observe histopathological damage in skin tissue; enzyme-linked immunosorbent assay (ELISA) was used to detect serum inflammatory cytokine levels. Concurrently, an in vitro inflammatory model was established using human immortalized keratinocytes (HaCaT). Cells were divided into cell control group, cell model group (LPS 1 μg·mL^-1), cell low- and high-dose Thc@NE@gel expreimental groups (10 and 30 μM Thc@NE@gel). Reactive oxygen species (ROS) were measured in each group using flow cytometry; serum inflammatory cytokine levels were detected by ELISA; Western blot analysis was performed to detect the expression of key proteins in the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) signaling pathway.

Thc@NE@gel was developed with a particle size of (195.30±5.20) nm, a zeta potential of (-24.51±1.45) mV, and a encapsulation efficiency of (72.70±0.67)%. The body weights of mice in the animal Thc@NE@gel low-, medium-, and high-dose treatment groups, the animal blank group, the animal model group, the Thc@NE group, and the positive control (dexamethasone) group on day 17 were (21.50±1.20), (22.30±1.15), (24.00±1.25), (26.20±1.30), (17.30±1.10), (18.20±1.15) and (17.50±1.05) g, respectively; immunoglobulin E(IgE) levels were (40.52±10.23), (32.84±9.65), (30.67±10.12), (21.23±3.45), (53.21±4.12), (56.45±5.89) and (64.32±12.14) ng·mL^-1; IL-17 levels were (48.23±8.12), (25.43±4.67), (30.21±9.87), (23.45±5.12), (84.56±12.34), (54.12±5.67), and (47.89±6.78) pg·mL^-1; IL-23 levels were (45.67±3.12), (44.23±2.98), (40.12±2.45), (25.34±7.12), (73.45±15.67), (55.23±6.78), and (24.56±1.89) pg·mL^-1; when comparing the animal animal model group with the animal blank group, all of the above inflammatory markers showed statistically significant differences (all P<0.05). Compared with the animal model group, the IgE and IL-17 levels in the animal medium- and high-dose groups of Thc@NE@gel, as well as the IL-23 levels in all dose groups, showed statistically significant differences (all P<0.05); the IgE levels in the positive control group showed no statistically significant difference compared with the animal model group (P>0.05). Furthermore, the relative protein expression levels of cGAS in the low-dose and high-dose cell Thc@NE@gel experimental groups, the cell blank group, and the cell model group were 1.15±0.12, 0.82±0.08, 1.00±0, and 1.65±0.18, respectively; the relative protein expression levels of STING were 0.95±0.10, 0.60±0.06, 1.00±0.00, and 1.65±0.15, respectively. Compared with the animal blank group, all of the aforementioned indicators in the cell model group showed statistically significant differences (all P<0.001).

Thc@NE@gel enhances the anti-inflammatory effects of Thc, providing new insights for the development of skin delivery systems for natural active ingredients; furthermore, by inhibiting the cGAS-STING pathway, Thc@NE@gel improves atopic dermatitis, offering a new mechanistic perspective for its treatment.

To establish a liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for determining the plasma concentration of the active component polymyxin E in patients treated with colistimethate sodium.

Polymyxin B1 was used as an internal standard, and solid phase extraction (SPE) was employed to process the samples. The chromatographic column was a Kinetex C₁₈ (3 mm×100 mm, 2.6 μm). Mobile phase A was an aqueous solution containing 0.1% formic acid and 5 mmol·L^-1 ammonium acetate, and mobile phase B was a methanol solution containing 0.1% formic acid. Gradient elution was performed at a flow rate of 0.5 mL·min^-1. An electrospray ionization (ESI) source was used with positive ion multiple reaction monitoring (MRM) for detection. The ion pairs for quantitative analysis were as follows: m/z 585.6→241.1 (polymyxin E1), m/z 578.6→227.2 (polymyxin E2), and m/z 602.6→101.2 (polymyxin B1). The selectivity, standard curve, residues, precision and accuracy, extraction recovery rate, matrix effect and stability of the method were investigated, and the plasma concentrations of polymyxin E1 and E2 in patients treated with colistimethate sodium were measured.

The linear relationships of polymyxin E1 and E2 concentrations were good within the ranges of 0.02–3.86 μg·mL^-1 and 0.03–5.65 μg·mL^-1, respectively. The lower limits of quantification (LLOQ) for polymyxin E1 and E2 were 0.02 μg·mL^-1 and 0.03 μg·mL^-1, respectively. The standard curve equations for polymyxin E1 and E2 are Y=4.55×10^-1X-2.92×10^-2 (r=0.994 2)、Y=8.61×10^-1X-1.38×10^-2 (r=0.996 4), respectively. The within-day and day-to-day precision, accuracy, extraction recovery, matrix effects, and stability of polymyxin E1 and E2 all met the methodological requirements. Using this method, the AUC of polymyxin E in 26 patients receiving colistimethate sodium ranged from 28.42 to 317.51 μg·mL^-1.

This method is accurate, sensitive, rapid, and stable, and can be used for the determination of the plasma concentrations of polymyxin E1 and E2 in human plasma.

To investigate the etiological factors and clinical characteristics of statin-associated myopathy in elderly patients.

A retrospective analysis was performed on elderly patients with statina-ssociated myopathy who were treated in the internal medicine department of our hospital from January 2017 to June 2024. Data including etiology, clinical manifestations, treatment process and prognosis were collected and analyzed.

A total of 21 elderly patients with statina-ssociated myopathy were enrolled, including 13 males and 8 females, with an average age of (77.33±9.61) years. Among them, 5 patients were diagnosed with rhabdomyolysis. According to the type of statin taken, patients were divided into 5 groups: atorvastatin group, rosuvastatin group, simvastatin group, pitavastatin group and Xuezhikang group. All patients received monotherapy without overlapping or combined use of different statins. The duration of statin therapy at onset ranged from 2 weeks to 10 years. Precipitating factors included infection, concomitant medications, stress and exercise. Among them, 12 cases were related to infection (9 pneumonia, 2 urinary tract infections, 1 intestinal infection), and 2 cases were associated with concomitant medications (quetiapine and cyclosporine A, respectively). Most patients had multiple comorbidities: hypertension in 90.48% (19 cases/21 cases), type 2 diabetes mellitus in 66.67% (14 cases/21 cases), coronary heart disease in 47.62% (10 cases/21 cases), and chronic kidney disease in 23.81% (5 cases/21 cases). Patients were on multiple concomitant medications, with a mean of 6 drugs used. Acute kidney injury occurred in 4 patients with myopathy and in 5 patients with rhabdomyolysis. After comprehensive treatment including statin discontinuation, fluid replacement, urine alkalinization and blood purification, all patients improved and no deaths occurred. Serum creatinine in patients with acute kidney injury returned to normal or baseline levels before onset.

Elderly patients with acute infection, concomitant medications and multiple comorbidities should be closely monitored for the risk of statinassociated myopathy or rhabdomyolysis. Acute kidney injury is common in such elderly patients. Early discontinuation of statins and comprehensive treatment including symptomatic fluid infusion and blood purification can significantly improve patient prognosis.

To analyze the role mechanism of xuesaitong injection (lyophilized) in the treatment of cerebral infarction by network pharmacology and molecular docking technology.

The intersection targets of five important active ingredients (Ginsenoside Rg1, Ginsenoside Rb1, Ginsenoside Re, Notoginsenoside R1, Ginsenoside Rd) in xuesaitong injection (lyophilized) and acute cerebral infarction were screened by database, and the target action network was constructed. Gene ontology (GO) pathway analysis and Kyoto encyclopedia of genes and genomes (KEGG) pathway enrichment analysis were performed by using digital-audio-video internet devince (DAVID) database, and molecular docking verification was performed.

A total of 61 non-redundant targets were screened for Panax notoginseng saponins, and 5 737 non-redundant targets were identified for cerebral infarction. The intersection of three databases yielded 64 common targets. After intersecting the drug targets with the disease targets, two overlapping targets were obtained: protein kinase C beta (PRKCB) and tumor necrosis factor (TNF). Intersection with the non-redundant disease targets yielded 51 overlapping targets. Based on network topology parameters and the intersection target results, caspase-3 (CASP3), TNF, nuclear factor kappa B subunit 1 (NFKB1), matrix metalloproteinase-9 (MMP9), tumor protein p53 (TP53), and PRKCB were selected for subsequent molecular docking. The results of GO functional enrichment analysis showed that in terms of biological processes, the target genes were mainly involved in the positive regulation of gene expression, the negative regulation of apoptosis process, and the positive regulation of miRNA transcription. In terms of cell components, the target genes were mainly located in extracellular space, extracellular region, blood, axon and protein complex. In terms of molecular function, the target proteins mainly had the same protein binding, protease binding, Heat shock protein 90 (HSP90) protein binding and other functions, and the enrichment results were statistically significant (all P<0.05). The results of KEGG enrichment analysis revealed that the potential targets of xuesaitong injection (lyophilized) in the treatment of cerebral infarction were enriched in advanced glycation end products-receptor for advanced glycation end products (AGE-RAGE) signaling pathway, lipid and atherosclerosis, fluid shear stress and atherosclerosis, proteoglycans in cancer, MAPK signaling pathway, thyroid hormone signaling pathway, apoptosis pathway and other signaling pathways, and the enrichment results were statistically significant (P<0.05). The results of molecular docking displayed that the main active ingredients of xuesaitong injection (lyophilized) had good binding ability with the core target protein, among which Ginsenoside Rg1 had the lowest binding energy with TNF, and CASP3, PRKCB showed strong binding with various active ingredients.

Xuesaitong injection (lyophilized) may play a multi-target comprehensive role in the treatment of cerebral infarction by regulating CASP3, TNF, NFKB1, MMP9, TP53, PRKCB and other key targets, acting on pathways such as apoptosis, inflammation and atherosclerosis.

To systematically elucidate the mechanism of action of Qizhi hypoglycemic tablets (QZT) in treating diabetic vascular complications, this study adopted the methods of network pharmacology and molecular docking.

Active ingredients and their corresponding targets of QZT were retrieved from traditional Chinese medicine systems pharmacology database and analysis platform (TCMSP) and other databases. Disease targets related to diabetic nephropathy, retinopathy, and peripheral neuropathy were collected from The human gene database (GeneCards) and online mendelian inheritance in man (OMIM). Overlapping targets between drugs and diseases were identified, and a protein-protein interaction (PPI) network was constructed. Gene ontology (GO) and kyoto encyclopedia of genes and genomes (KEGG) enrichment analyses were performed using the database for annotation, visualization, and integrated discovery (DAVID). Molecular docking was used to validate the binding interactions between key active components and core targets.

A total of 116 active ingredients, 2 245 disease-related targets, and 354 common targets were obtained. Core targets such as proto-oncogene tyrosine-protein kinase (SRC), signal transducer and activator of transcription 3 (STAT3), estrogen receptor 1 (ESR1), and RAC-alpha serine/threonine-protein kinase (AKT1) were identified. GO and KEGG analyses revealed that the therapeutic effects of QZT were primarily mediated through key pathways including phosphatidylinositol 3-kinase/Akt signaling pathway (PI3K-Akt) and advanced glycation end products-receptor for advanced glycation end products signaling pathway (AGE-RAGE). Molecular docking confirmed stable binding of core components including apigenin, baicalein, and 4′,7-dihydroxyflavanone (DFV) to the core targets.

This study preliminarily clarifies the multi-component, multi-target, and multi-pathway mechanism of QZT against diabetic vascular complications, providing a theoretical basis for its clinical application and further investigation.

To analyze the gene polymorphism of aspirin drug-related genes platelet membrane glycoprotein Ⅲa phospholipase A2 (GPⅢa PLA2), platelet endothelial aggregation receptor 1 (PEAR1), glutathione S-transferase P1 (GSTP1) and prostaglandin endoperoxide synthase 1 (PTGS1) in patients with ischemic stroke in Beijing.

Patients with ischemic stroke in the neurology department of our hospital were included as research subjects, and the polymorphism of drug-related gene loci was detected by fluorescence in situ hybridization sequencing.

The overall mutation rate of aspirin related genes was 75.42% (356 cases/472 cases). GPⅢa PLA 2 typing included 458 cases TT type, 11 cases TC type and 3 cases CC type, C allele frequency was 1.80% (17 cases/944 cases); PEAR1 typing included 187 cases GG type, 224 cases GA type and 61 cases AA type, A allele frequency was 36.65% (346 cases/944 cases); GSTP1 typing included 295 cases AA type, 160 cases GA type and 17 cases GG type, G allele frequency was 20.55% (194 cases/944 cases); typing of PTGS1 included 50 cases AA type, and the frequency of G allele was 0. GPⅢa PLA2 TT+PEAR1 GA+GSTP1 AA was the most common combination, accounting for 138 cases (29.24%). There was no statistically significant difference in gene polymorphisms of GPⅢa PLA2, PEAR1, GSTP1 between different genders and ages (all P>0.05). The genotype and allele distributions of GPⅢa PLA2, PEAR1, GSTP1 and PTGS1 in patients with ischemic stroke in Beijing were not statistically significantly different from those in Zaozhuang, Nanjing and Shanghai (all P>0.05), while the genotype and allele distributions of GPⅢa PLA2, PEAR1 and GSTP1 were statistically significantly different from those in Guangdong (all P<0.05).

PEAR1 and GSTP1 are the main mutations in aspirin drug-related genes in patients with ischemic stroke in Beijing. The mutation ratio of GPⅢa PLA2 and PTGS1 gene is low, and the gene polymorphism in Beijing is different from that in other regions.

To systematically evaluate the efficacy and safety of lecarnitine in the treatment of patients with myocardial damage.

Search databases such as PubMed, Embase, Cochrane Library, CNKI, Wanfang Database, etc. randomized controlled trials (RCTS) comparing L-carnitine with sodium creatine phosphate, sodium fructobisphosphonate, trimetazidine and coenzyme Q10 for the treatment of myocardial damage were included according to the inclusion and exclusion criteria. The search period for all was from the establishment of the database to May 2024. Meta-analysis was performed using RevMan 5.3 and Stata 14.0.

A total of 12 RCTs were included, involving a total of 1 408 patients. Meta-analysis showed that the total effective rate of levocarnitine was 89.53% (556 cases/621 cases), which was significantly higher than that [83.98% (519 cases/618 cases)]of the control group [OR=1.83, 95% CI (1.10~3.06), P<0.05]; the incidence of adverse drug reactions of levocarnitine and the control group was 2.47% (9 cases/364 cases) and 3.31% (12 cases/362 cases) with no statistically significant difference [OR=0.83, 95% CI (0.17~4.18), P>0.05]. The creatine kinase (CK) levels of L-carnitine group and the control group were(203.04±34.59) and (238.28±33.97)U·L^-1, respectvely [OR=-26.81, 95% CI (-47.43~-6.18), P<0.01]; the creatine kinase isoenzyme MB (CK-MB) levels were (21.64±10.76) and (26.71±14.48)U·L^-1, respectvely [OR=-4.19, 95% CI (-6.70~-1.67), P<0.001]were significantly better than those of . There was no statistically significant difference in the levels of lactate dehydrogenase (LDH) and cardiac troponin Ⅰ (cTnⅠ) of L-carnitine compared with the control group (all P>0.05).

The effectiveness of levocarnitine in the treatment of myocardial damage is relatively good, and there are no obvious adverse reactions.